论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
虎杖苷对抗缺血再灌注损伤的潜力:药理病理机制关联的新见解
Received 27 November 2024
Accepted for publication 17 February 2025
Published 6 March 2025 Volume 2025:19 Pages 1585—1594
DOI https://doi.org/10.2147/DDDT.S508851
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Tamer M. Ibrahim Abdelrehim
Zhicheng Sun,1– 3 Xiyang Wang,1– 3 Xiaoyang Pang1– 3
1Department of Spine Surgery, Xiangya Hospital of Central South University, Changsha, People’s Republic of China; 2Hunan Engineering Laboratory of Advanced Artificial Osteo-Materials, Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 3National Clinical Research Center of Geriatric Disorders, Xiangya Hospital of Central South University, Changsha, People’s Republic of China
Correspondence: Xiaoyang Pang, Department of Spine Surgery, Xiangya Hospital of Central South University, Changsha, People’s Republic of China, Email xiaoyangpang@163.com
Abstract: Ischemia-reperfusion injury is a multi-tissue/organ susceptible and highly destructive disease. The complex pathological mechanisms of ischemia-reperfusion injury make its prevention and treatment highly challenging, and the development of novel drugs with pharmacological pleiotropy that can target multiple pathological mechanisms has become the focus of current drug research. Polydatin is a traditional Chinese medicine monomer with pleiotropic pharmacological effects, and existing research evidence suggests that polydatin has strong protective potential against ischemia-reperfusion injury. However, the mechanism of polydatin against ischemia-reperfusion injury is still unclear. In this review, the extensive pharmacological-pathological mechanism associations between polydatin and ischemia-reperfusion injury have been described from the perspectives of inflammatory response, oxidative stress, apoptosis, autophagy, ferroptosis, and cellular pyroptosis, which will provide references to the basic and applied research of polydatin in the field of ischemia-reperfusion injury.
Keywords: polydatin, ischemia-reperfusion injury, pharmacological mechanism, pathological mechanism